WO2016129802A2 - Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 - Google Patents
Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2016129802A2 WO2016129802A2 PCT/KR2015/013791 KR2015013791W WO2016129802A2 WO 2016129802 A2 WO2016129802 A2 WO 2016129802A2 KR 2015013791 W KR2015013791 W KR 2015013791W WO 2016129802 A2 WO2016129802 A2 WO 2016129802A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- asthma
- pkr
- bronchial asthma
- pkr inhibitor
- prevention
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 74
- 239000003112 inhibitor Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims abstract description 52
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 24
- 210000003979 eosinophil Anatomy 0.000 claims abstract description 13
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 12
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 108010037623 eIF-2 Kinase Proteins 0.000 claims description 7
- 102000010982 eIF-2 Kinase Human genes 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 4
- VFBGXTUGODTSPK-BAQGIRSFSA-N (8z)-8-(1h-imidazol-5-ylmethylidene)-6h-pyrrolo[2,3-g][1,3]benzothiazol-7-one Chemical compound O=C1NC2=CC=C3N=CSC3=C2\C1=C\C1=CN=CN1 VFBGXTUGODTSPK-BAQGIRSFSA-N 0.000 claims description 3
- 208000024716 acute asthma Diseases 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 239000012530 fluid Substances 0.000 abstract description 7
- 208000037883 airway inflammation Diseases 0.000 abstract description 5
- 235000013402 health food Nutrition 0.000 abstract description 5
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract description 4
- 230000010085 airway hyperresponsiveness Effects 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 230000003448 neutrophilic effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 16
- 108010088751 Albumins Proteins 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000002969 egg yolk Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 12
- 108010000912 Egg Proteins Proteins 0.000 description 10
- 102000002322 Egg Proteins Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 235000013345 egg yolk Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000009610 hypersensitivity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
- 229960002329 methacholine Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 230000008372 airway inflammatory response Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- -1 severe asthma Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Definitions
- the present invention relates to a composition for the prevention or treatment of bronchial asthma containing an PKR (RNA-dependent protein kinase) inhibitor and derivatives thereof as an active ingredient.
- PKR RNA-dependent protein kinase
- Bronchial asthma is a chronic disease that causes bronchial hypersensitivity and intermittent airway contractions due to chronic inflammation of the airways, causing respiratory distress, and there is no known cure for it yet.
- Bronchial asthma is a very common disease that is reported to affect about 5 to 10% of the population in most countries around the world, including Korea, and its prevalence has increased even more recently due to environmental changes. It is increasing.
- asthma Most asthma are allergic and are characterized by chronic airway inflammation and bronchial hyperresponsiveness.
- asthma has been reported with various pathophysiology and irreversible airway pathologic changes.
- persistent inflammatory reactions cause acute and chronic airway and lung damage, and are classified into inflammatory reactions and fibrosis.
- airway remodeling There is a common pathophysiological process, and asthma is commonly referred to as airway remodeling to refer to these various pathological changes. With these changes, no effective treatment is currently available, providing a pathological cause of severe asthma.
- asthma is a pathophysiological inflammation of cytokines produced by T-helper type 2 (Th2) immune cells, which are caused by proliferation, differentiation and activation of inflammatory cells, which are transferred to and invaded into the airways and surrounding airways. It is recognized as a disease.
- inflammatory cells such as activated eosinophils, mast cells, and alveolar macrophages are known to induce bronchial contraction and increase eosinophils by secreting various inflammatory mediators, and the increase of inflammatory mediators produced by eosinophils is asthma again. It is an important factor that worsens.
- asthma treatment agents are effective in the production of Th2 cytokines such as interleukin-4, interleukin-5, and interleukin-13, which are involved in the production and activation of inflammatory cells (lymphocytes, eosinophils, neutrophils) in lung tissue. It is mainly focused on suppressing and inducing suppression of the airway inflammatory response.
- Th2 cytokines such as interleukin-4, interleukin-5, and interleukin-13, which are involved in the production and activation of inflammatory cells (lymphocytes, eosinophils, neutrophils) in lung tissue. It is mainly focused on suppressing and inducing suppression of the airway inflammatory response.
- Inhaled steroid preparations which have recently been used as the most effective treatments, work well for typical asthma, but are less effective for steroid resistance or severe asthma of 5-15% of all patients. Unlike other patient groups, such a patient group has a low response to a therapeutic agent, which is difficult to treat. Patients who are unable to satisfactorily control their asthma despite the maximum use of various inhalant steroids, such as severe asthma, refractory asthma, or difficult to treat asthma They are characterized by persistent symptoms, frequent acute exacerbations, frequent use of systemic steroids, and frequent need for fast-acting bronchodilators. The increased prevalence and associated mortality of asthma in the development of various treatments is due to the lack of fundamental treatment for the common etiology of refractory severe asthma. Therefore, recent trends in the development of asthma treatments have been focused on the development of drugs with mechanisms that can overcome the characteristics of severe asthma.
- Severe asthma unlike typical asthma in adults is more likely to have a neutrophil inflammatory response, acute exacerbation, and a severe inflammatory response and airway hypersensitivity without steroid response.
- the importance of innate immunity is emphasized in the occurrence of the neutrophil severe asthma.
- RNA-dependent protein kinase is an RNA-dependent protein kinase, specifically serine / threonine kinase, which plays an important role in the innate immune response that works when a viral infection occurs in vivo.
- PKR has been reported to play a role in the intracellular signaling system of Toll-like receptor, a receptor system that recognizes external infectious agents, and has been reported to affect the immune response in the lung. The therapeutic effect of the disease in stages and diseases using the biological model has not been evaluated.
- PKR inhibitors have a therapeutic effect on severe asthma, and there are no studies on them. Therefore, the present inventors completed the present invention by confirming that the PKR inhibitor has an excellent treatment for severe asthma, as a result of using a PKR inhibitor to develop a new drug having a therapeutic effect on severe asthma.
- the present invention provides a composition for preventing or treating bronchial asthma, which contains a PKR inhibitor and a derivative thereof as an active ingredient.
- PKR inhibitors and derivatives thereof reduce the total number of inflammatory cells, the number of eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid of neutrophils with severe asthma-induced mice, reduce the degree of airway inflammation and airway hyperresponsiveness, and mediate inflammation It can be used as medicines and dietary supplements useful for the prevention, improvement or treatment of bronchial asthma.
- FIG. 1 is a diagram showing the effect of the PKR inhibitor of the present invention on the total number of inflammatory cells, eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid of the neutrophil severe asthma mouse model.
- FIG. 2 is a diagram illustrating the effect of the PKR inhibitor of the present invention on the peribronchiolitis and perivascular inflammation in the lung tissue of the neutrophil severe asthma mouse model.
- FIG. 3 is a diagram showing the effect of the PKR inhibitor of the present invention on airway hypersensitivity in the model of neutrophil severe asthma.
- FIG. 4 is a diagram showing the effect of the PKR inhibitor of the present invention on the cytokines and chemokines in the lung tissue of the neutrophil severe asthma mouse model.
- the present invention is a PKR (RNA-dependent protein kinase) inhibitor represented by the following formula [6,8-Dihydro-8- (1H-imidazol-5-ylmethylene) -7H-pyrrolo [2,3-g] benzothiazol-7 -one] and its derivatives as an active ingredient provides a composition for the prevention, improvement or treatment of bronchial asthma.
- PKR RNA-dependent protein kinase
- the composition includes a pharmaceutical composition and a food composition.
- RNA-dependent protein kinase (PKR) inhibitors of the present invention act to inhibit the activity of RNA dependent protein kinase in vivo.
- the PKR inhibitor is [6,8-Dihydro-8- (1H-imidazol-5-ylmethylene) -7H-pyrrolo [2,3-g] benzothiazol having a molecular formula of C 3 H 8 N 4 OS as in Chemical Formula 1 -7-one].
- PKR inhibitors and derivatives thereof reduce the total number of inflammatory cells and the number of lymphocytes, neutrophils, eosinophils in bronchoalveolar lavage fluid of neutrophils with severe asthma-induced mice, reduce airway hyperresponsiveness, Th2 cytokines and Reduces airway inflammation
- PKR inhibitors and derivatives thereof according to the present invention can be used as medicines and health functional foods useful for the prevention, improvement or treatment of bronchial asthma.
- Bronchial asthma of the present invention includes, but is not limited to, severe bronchial asthma and acute asthma.
- the severe bronchial asthma may be induced through sensitization of lipopolysaaccharide (LPS) and egg yolk albumin (ovalbumin, OVA).
- LPS lipopolysaaccharide
- OVA egg yolk albumin
- composition of the present invention may contain at least one known active ingredient having a prophylactic or therapeutic effect of bronchial asthma together with a PKR inhibitor and a derivative thereof.
- composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration.
- the pharmaceutically acceptable carrier may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, antioxidants, Other conventional additives such as buffers and bacteriostatic agents can be added.
- Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
- composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the weight, age, sex and health of the patient. The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease.
- the daily dosage of the PKR inhibitor and its derivatives is about 250-1000 mg / kg, preferably about 500 mg / kg, preferably administered once to several times a day.
- composition of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers for the prevention or treatment of bronchial asthma.
- the composition of the present invention may be added to a dietary supplement for the purpose of preventing bronchial asthma.
- the PKR inhibitor and derivatives thereof of the present invention may be added as they are or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
- the PKR inhibitors and derivatives thereof of the present invention are added in an amount of up to 15% by weight, preferably up to 10% by weight based on the raw materials.
- the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
- Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and includes all of the dietary supplements in the conventional sense.
- the health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage.
- Natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.
- sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
- the proportion of the natural carbohydrate is generally about 0.01-0.20 g, preferably about 0.04-0.10 g per 100 ml of the composition of the present invention.
- the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage.
- the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.
- the experimental animals were purchased from Orient Bio Co., Ltd. (Seongnam, Korea) of 8-week-old female C57BL / 6 mice.
- the experimental group was divided into four groups, and five C57BL / 6 mice were allocated to one group.
- One animal was inhaled with saline and treated with vehicle, and the other three animals were sensitized with egg yolk albumin (ovalbumin, OVA) and lipopolysaccharide (LPS), and then inhaled with egg yolk albumin to induce asthma.
- OVA egg yolk albumin
- LPS lipopolysaccharide
- mice Female C57BL / 6 mice were sensitized with yolk albumin (OVA) and liposaccharide lipid (LPS), and then euthanized by inhalation of yolk albumin to induce asthma 48 hours after induction. Thereafter, a fixed solution (0.8% formalin, 4% acetic acid) was injected into the organs and lungs of the mouse, and the lungs were separated from the mouse and fixed using 10% neutral formalin. After dehydration of the lung tissue, a block was made using paraffin, and sections were cut by using a micro cutter to a thickness of 4 ⁇ m. Sections were placed on the glass, paraffin was removed, stained with H & E (hematoxylin and eosin), and lung tissue was observed at 20 magnification using an optical microscope. The results are shown in FIG. 2.
- OVA yolk albumin
- LPS liposaccharide lipid
- the change in airway function was measured after the administration of methacholine in aerosol form through the airway of the mouse.
- the dose was increased from 5.0 mg / ml to 50 mg / ml with methacholine administered via a ventilator and airway hypersensitivity (Rrs) was continuously measured.
- Airway hypersensitivity was evaluated as a percentage of baseline when the saline control group was administered the maximum of the Rrs values measured at each methacholine concentration, and the results are shown in FIG. 3.
- the airway resistance dose response curve of the neutral severity asthma-induced mouse model is shifted to the left compared to normal mice inhaled with saline only, and Rrs when the methacholine concentration is 25 and 50 mg / ml. Although the value increased significantly, it was confirmed that the airway dose response curve was shifted to the right and the Rrs value was significantly decreased in the PKR inhibitor-treated group. This indicates that PKR inhibitors reduce airway hypersensitivity by egg yolk albumin and liposaccharide lipids.
- cytokines and chemokines were confirmed by Western blotting methods for the corresponding proteins in lung tissue.
- the protein was extracted from lung tissue of a homogenized neutral constitutive severe asthma-induced mouse, and the sample was completed to maintain a constant concentration of protein.
- the sample was then loaded onto an SDS-PAGE gel, anti-IL-4 antibody for IL-4 (Serotec, UK) and anti-IL-5 antibody for IL-5 (SantaCruz Biotechnology, USA), Quantification using anti-IL-13 and anti-IL-17 antibodies (R & D Systems, USA) for IL-13 and IL-17 and anti-KC antibodies (KioVision, USA) for keratinocyte-induced chemokine (KC)
- FIGS. 4A to 4E The results are shown in FIGS. 4A to 4E.
- tablets were prepared by tableting according to a conventional method for producing tablets.
- the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
- Injectables were prepared by mixing the above ingredients per ampoule (2 ml) according to the usual method for preparing injectables.
- Vitamin B6 0.5 mg
- composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
- the granules may be prepared and used for preparing a health food composition according to a conventional method.
- the resulting solution is filtered and obtained in a sterilized 2 l container, sealed sterilized and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
- composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
Abstract
Description
Claims (5)
- 제1항에 있어서, 상기 기관지 천식은 중증 기관지 천식 또는 급성 천식인 것을 특징으로 하는, 기관지 천식의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 PKR 저해제는 천식에 의한 염증세포수, 호산구, 중성구 및 림프구의 수를 감소시키는 것을 특징으로 하는 기관지 천식의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 PKR 저해제는 천식에 의한 기관지 주위염 및 혈관주위 염증을 감소시키는 것을 특징으로 하는 기관지 천식의 예방 또는 치료용 약학적 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/547,030 US10292969B2 (en) | 2015-02-12 | 2015-12-16 | Composition for prevention or treatment of bronchial asthma comprising PKR inhibitor as active ingredient |
GB1712767.1A GB2550759B (en) | 2015-02-12 | 2015-12-16 | Composition for prevention or treatment of bronchial asthma comprising PKR inhibitor as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150021423A KR101668074B1 (ko) | 2015-02-12 | 2015-02-12 | Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 |
KR10-2015-0021423 | 2015-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016129802A2 true WO2016129802A2 (ko) | 2016-08-18 |
WO2016129802A3 WO2016129802A3 (ko) | 2016-10-06 |
Family
ID=56615649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/013791 WO2016129802A2 (ko) | 2015-02-12 | 2015-12-16 | Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10292969B2 (ko) |
KR (1) | KR101668074B1 (ko) |
GB (1) | GB2550759B (ko) |
WO (1) | WO2016129802A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102017799B1 (ko) | 2019-03-22 | 2019-09-03 | 김성기 | 천식 완화 또는 치료용 생약 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69906149T2 (de) * | 1998-12-17 | 2003-12-18 | Hoffmann La Roche | 4,5-azolo-oxindole |
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
CA2631647A1 (en) * | 2005-11-30 | 2007-06-07 | Nestec S.A. | Use of branched-chain amino acids for the treatment of muscle loss |
CN101868235A (zh) * | 2007-11-26 | 2010-10-20 | 雀巢产品技术援助有限公司 | 抑制dsRNA-依赖性蛋白激酶激活和抑制肿瘤生长的组合物和方法 |
WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
-
2015
- 2015-02-12 KR KR1020150021423A patent/KR101668074B1/ko active IP Right Grant
- 2015-12-16 GB GB1712767.1A patent/GB2550759B/en active Active
- 2015-12-16 US US15/547,030 patent/US10292969B2/en active Active
- 2015-12-16 WO PCT/KR2015/013791 patent/WO2016129802A2/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR101668074B1 (ko) | 2016-10-21 |
WO2016129802A3 (ko) | 2016-10-06 |
GB2550759B (en) | 2020-11-25 |
US10292969B2 (en) | 2019-05-21 |
GB201712767D0 (en) | 2017-09-20 |
GB2550759A (en) | 2017-11-29 |
US20180000794A1 (en) | 2018-01-04 |
KR20160099756A (ko) | 2016-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
KR102204299B1 (ko) | 담팔수 추출물을 유효성분으로 포함하는 코로나 바이러스 치료제 | |
KR101262870B1 (ko) | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 | |
WO2012145946A1 (zh) | 一种麦冬多糖提取物在制备具有减肥功能的食品添加剂、保健品或药物中的应用 | |
KR100970739B1 (ko) | 황련 추출물을 유효성분으로 함유하는 호흡기 질환의 예방및 치료용 조성물 | |
KR100860080B1 (ko) | 항염, 항알레르기 및 항천식 활성을 갖는 꼬리풀속 식물추출물을 함유하는 약학조성물 | |
JP2008542363A (ja) | 抗炎、抗アレルギーおよび抗喘息活性を有するPseudolysimachionlongifolium抽出物およびこれから分離されたカタルポール誘導体を含有する薬学組成物 | |
EP3443972A1 (en) | Pharmaceutical composition for preventing or treating respiratory disease comprising extract of justicia procumbens l. | |
KR20220094115A (ko) | 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 대사질환 예방 또는 치료용 조성물 | |
WO2016186349A2 (ko) | 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물 | |
WO2016129802A2 (ko) | Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 | |
KR101964054B1 (ko) | 금은화 추출물을 포함하는 크론병 치료 또는 예방용 약학조성물 | |
US20230398168A1 (en) | Use of effective part extract of monochasma savatieri in preparation of drug for treating inflammatory disease or tumor | |
KR101855894B1 (ko) | p-coumaric acid를 포함하는 호흡기 질환의 예방 또는 치료 효과를 갖는 약학조성물 | |
US20160263130A1 (en) | Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component | |
KR20200021738A (ko) | 장수만리화 추출물을 포함하는 호흡기 질환 예방, 개선 또는 치료용 조성물 | |
KR20210058760A (ko) | 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
JPH09241157A (ja) | リソスペルメートb含有肝臓保護作用医薬組成物 | |
EP3928785A1 (en) | Medicine and food for preventing or treating covid-19, and application thereof | |
KR100822760B1 (ko) | 항염, 항알레르기 및 항천식 활성을 갖는 헐떡이풀추출물을 함유하는 조성물 | |
WO2012067322A1 (ko) | 페닐부틸산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 천식 치료용 약학적 조성물 | |
WO2022145711A1 (ko) | 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 대사질환 예방 또는 치료용 조성물 | |
KR102487701B1 (ko) | 기관지염 또는 호흡기 질환 개선효능을 갖는 병풀 추출물 및 이를 유효성분으로 포함하는 조성물 및 이의 용도 | |
WO2023204364A1 (ko) | 고량강 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물 | |
KR102568093B1 (ko) | 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15882164 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15547030 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 201712767 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20151216 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15882164 Country of ref document: EP Kind code of ref document: A2 |